TP53 and ovarian serous adenocarcinoma: Similarly, genomic studies of ovarian cancer also revealed frequent TP53 mutations in high-grade serous ovarian carcinomas [9], and the prevalence of mutations affecting the PTEN/PI3K, WNT, RAS, and SWI/SNF pathways in non-serous ovarian cancers (e.g., endometrioid ovarian cancer) [10].